Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTERACTIVE EFFECTS OF SUBANESTHETIC KETAMINE AND SUBHYPNOTIC LORAZEPAM IN HUMANS
Autore:
KRYSTAL JH; KARPER LP; BENNETT A; DSOUZA DC; ABIDARGHAM A; MORRISSEY K; ABISAAB D; BREMNER JD; BOWERS MB; SUCKOW RF; STETSON P; HENINGER GR; CHARNEY DS;
Indirizzi:
VET ADM MED CTR,PSYCHIAT SERV 116A W HAVEN CT 06516 YALE UNIV,SCH MED,DEPT PSYCHIAT NEW HAVEN CT 06520 CONNECTICUT MENTAL HLTH CTR,ABRAHAM RIBICOFF RES FACIL NEW HAVEN CT 06519 CORNELL UNIV,MED CTR,DEPT NEUROL NEW YORK NY 10021 NEW YORK STATE PSYCHIAT INST & HOSP NEW YORK NY 10032 UNIV MICHIGAN,MED CTR,UPJOHN CTR CLIN PHARMACOL ANN ARBOR MI 48109
Titolo Testata:
Psychopharmacology
fascicolo: 3, volume: 135, anno: 1998,
pagine: 213 - 229
Fonte:
ISI
Lingua:
ENG
Soggetto:
TOTAL INTRAVENOUS ANESTHESIA; NMDA RECEPTOR ANTAGONISTS; D-ASPARTATE RECEPTORS; SCHIZOPHRENIC-PATIENTS; CEREBROSPINAL-FLUID; PREFRONTAL CORTEX; NEGATIVE SYMPTOMS; HEALTHY-SUBJECTS; BRAIN-REGIONS; BLOOD-FLOW;
Keywords:
KETAMINE; N-METHYL-D-ASPARTATE; GLUTAMATE; PSYCHOSIS; DISSOCIATION; GABA; BENZODIAZEPINE; MEMORY; ATTENTION; FRONTAL CORTEX; WISCONSIN CARD SORTING TEST;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
109
Recensione:
Indirizzi per estratti:
Citazione:
J.H. Krystal et al., "INTERACTIVE EFFECTS OF SUBANESTHETIC KETAMINE AND SUBHYPNOTIC LORAZEPAM IN HUMANS", Psychopharmacology, 135(3), 1998, pp. 213-229

Abstract

Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist with psychotogenic and dissociative effects in healthy humans. These cognitive and perceptual effects in humans are reportedly reduced by benzodiazepine premedication. This study assessed the interactive effects of aketamine (IV bolus of 0.26 mg/kg followed by an infusion of 0.65 mg/kg per hour) and lorazepam 2 mg., PO, in humans. Twenty-three healthy subjects completed 4 test days involving the oral administration of lorazepam or matched placebo 2h prior to the IV infusion of ketamine or placebo. Ketamine: I) produced behaviors similar to the positive and negative symptoms of schizophrenia as assessed by the Brief Psychiatric Rating Scale (BPRS); 2) evoked perceptual alterations as measured by the Clinician-Administered Dissociative States Scale (CADSS); 3) impaired performance on the Wisconsin Card Sorting Test (WCST) and other tests sensitive to frontal cortical impairment; and 4) had amnestic effects. Lorazepam produced attention impairments, concrete proverb interpretations, and recall impairments. Lorazepam reduced ketamine-associated emotional distress and there was a non-significant trend for it to decrease perceptual alterations produced by ketamine. However, it failed to reduce many cognitive and behavioral effects of ketamine, including psychosis. Further, lorazepam exacerbated the sedative, attention-impairing, and amnestic effects of ketamine. There was no evidence of pharmacokinetic interaction between these medications. These data suggest that subhypnotic lorazepam and ketamine show a spectrum of interactive effects, ranging from antagonism to potentiation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 18:18:14